Novo Nordisk Q3 profit reaches $2.58 billion
Key points
- Novo Nordisk reported third-quarter 2026 net profit of $2.58 billion, with adjusted earnings of $0.89 per share.
- Adjusted earnings exceeded analysts' $0.81 estimate, while revenue reached $12.19 billion, beating the $11.39 billion forecast.
- The company raised its 2026 adjusted sales and operating profit outlook, forecasting growth between -2% and +2% at constant exchange rates.
Novo Nordisk (NYSE:NVO) reported third-quarter 2026 net profit of $2.58 billion, as earnings and revenue exceeded Wall Street expectations.
Adjusted earnings reached $0.89 per share, surpassing the $0.81 average estimate from four analysts surveyed by Zacks Investment Research.
Revenue totaled $12.19 billion, exceeding the $11.39 billion forecast from three analysts surveyed by Zacks.
Reported earnings were $0.58 per share, while adjusted earnings excluded non-recurring expenses affecting the company's quarterly results.
Novo Nordisk raised its 2026 adjusted sales and operating profit growth forecasts to between -2% and +2% at constant exchange rates.
The Danish drugmaker develops treatments for diabetes, obesity and other chronic conditions, including its Ozempic and Wegovy products.
Novo Nordisk's obesity treatment sales increased 22% at constant exchange rates to DKK 26.2 billion during the quarter.
